However, patients with stage IV lung adenocarcinoma and KRASmut seem to benefit from long-term response rates, particularly after first-line PD-1 blockade, compared with patients receiving platinum doublet treatment (34). Here, PDCD1 is linked to lung adenocarcinoma.